LEGN Stock Forecast

Outlook: LEGN is assigned short-term B1 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-term Tactic¹ :
Dominant Strategy :
Time series to forecast n: for Weeks²
ML Model Testing : Deductive Inference (ML)
Hypothesis Testing : Sign Test
Surveillance : Major exchange and OTC

¹Short-term revised.

²Time series is updated based on short-term trends.

Key Points

This exclusive content is only available to premium users.

About LEGN

This exclusive content is only available to premium users.

This exclusive content is only available to premium users.

ML Model Testing

F(Sign Test)^6,7= $\begin{array}{cccc}{p}_{\mathrm{a}1}& p_{\mathrm{a}2}& \dots & p_{1n}\\ & ⋮\\ p_{j1}& p_{j2}& \dots & p_{jn}\\ & ⋮\\ p_{k1}& p_{k2}& \dots & p_{kn}\\ & ⋮\\ p_{n1}& p_{n2}& \dots & p_{nn}\end{array}$ X R(Deductive Inference (ML))^3,4,5 X S(n):→ 8 Weeks $\sum _{i=1}^n\left(a_i\right)$

n:Time series to forecast

p:Price signals of LEGN stock

j:Nash equilibria (Neural Network)

k:Dominated move of LEGN stock holders

a:Best response for LEGN target price

 

For further technical information as per how our model work we invite you to visit the article below: 

How do KappaSignal algorithms actually work?

LEGN Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Legend Biotech ADS Financial Outlook and Forecast

Legend Biotech Corporation (LEGN) presents a dynamic financial outlook, primarily driven by the ongoing success and expansion of its CAR-T therapy, cilta-cel (Carvykti). The company's revenue generation is heavily concentrated on this breakthrough treatment for relapsed and refractory multiple myeloma. Analysts project continued growth in sales for Carvykti, fueled by increasing patient access, broader physician adoption, and potential indications in earlier lines of therapy. This growth trajectory is supported by robust clinical data demonstrating Carvykti's efficacy and safety profile. Furthermore, LEGN is investing significantly in its research and development pipeline, which includes multiple early-stage and mid-stage assets across various therapeutic areas such as oncology and autoimmune diseases. These investments, while incurring substantial costs, represent potential future revenue streams and diversification opportunities that contribute to the long-term financial narrative.

The financial forecast for LEGN is characterized by a ramp-up in revenue from Carvykti, coupled with increasing operating expenses associated with commercialization, manufacturing scale-up, and R&D activities. Gross margins for Carvykti are expected to improve as production efficiencies are realized and sales volumes increase. However, the company's profitability in the near to medium term will be a key area of scrutiny. Significant upfront investments in manufacturing capacity to meet anticipated demand for Carvykti, along with ongoing clinical trials for pipeline assets, are likely to keep operating expenses elevated. This necessitates a careful management of cash burn and a strategic approach to capital allocation. Partnerships and collaborations, such as the existing one with Janssen for Carvykti, play a crucial role in sharing development and commercialization costs, thereby mitigating some of the financial burden on LEGN.

Looking ahead, LEGN's financial health will be intrinsically linked to the sustained commercial performance of Carvykti and the successful advancement of its R&D pipeline. The market for CAR-T therapies is competitive, and LEGN will need to continuously demonstrate the value proposition of Carvykti against existing and emerging treatments. Key financial metrics to monitor will include year-over-year revenue growth for Carvykti, the pace of its market penetration, and the progression of its pipeline candidates through clinical development. The company's ability to manage its operational costs, particularly manufacturing and R&D expenditures, will be critical in achieving sustained profitability. Strategic financing activities, including potential equity raises or debt financing, may be utilized to fund its ambitious growth plans and R&D initiatives, underscoring the importance of market confidence in its long-term prospects.

The prediction for LEGN's financial outlook is generally positive, underpinned by the strong clinical profile and market reception of Carvykti. The forecast anticipates significant revenue growth in the coming years, driven by expanding market access and potential label expansions. However, considerable risks exist. Intensifying competition in the CAR-T space, potential manufacturing challenges or delays in scaling up production to meet demand, and unforeseen clinical trial setbacks for pipeline candidates could negatively impact financial performance. Furthermore, pricing pressures and reimbursement challenges in different healthcare systems globally represent ongoing risks for a high-cost therapy like Carvykti. The company's ability to navigate these complexities and effectively execute its commercial and R&D strategies will ultimately determine its long-term financial success.

Rating	Short-Term	Long-Term Senior
Outlook	B1	B2
Income Statement	B3	B3
Balance Sheet	Caa2	Caa2
Leverage Ratios	B2	Baa2
Cash Flow	B1	Caa2
Rates of Return and Profitability	Baa2	Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

References

1. Greene WH. 2000. Econometric Analysis. Upper Saddle River, N J: Prentice Hall. 4th ed.
2. Armstrong, J. S. M. C. Grohman (1972), "A comparative study of methods for long-range market forecasting," Management Science, 19, 211–221.
3. Mikolov T, Chen K, Corrado GS, Dean J. 2013a. Efficient estimation of word representations in vector space. arXiv:1301.3781 [cs.CL]
4. Bengio Y, Schwenk H, Senécal JS, Morin F, Gauvain JL. 2006. Neural probabilistic language models. In Innovations in Machine Learning: Theory and Applications, ed. DE Holmes, pp. 137–86. Berlin: Springer
5. V. Borkar. Q-learning for risk-sensitive control. Mathematics of Operations Research, 27:294–311, 2002.
6. Artis, M. J. W. Zhang (1990), "BVAR forecasts for the G-7," International Journal of Forecasting, 6, 349–362.
7. Chernozhukov V, Newey W, Robins J. 2018c. Double/de-biased machine learning using regularized Riesz representers. arXiv:1802.08667 [stat.ML]